No, GLP-1 receptor agonists should not replace statins for cholesterol management
Studies have shown that the NLRP3 inflammasome is also involved in other skin diseases, such as psoriasis, urticaria, and bullous pemphigoid (179)
It also suppresses the release of glucagon, a hormone that raises blood glucose, and slows gastric emptying, which means food moves more slowly from the stomach into the small intestine
the active ingredient tirzepatide is FDA-approved in commercial formulations such as Mounjaro and Zepbound
& New, EJ Reversible fluorescent probes for biological redox states
The site of injection (abdomen, thigh, or upper arm) can affect the rate of subcutaneous absorption